Coronavirus: Astrazeneca lance la 1ère phase de l'essai clinique de son vaccin au Japon

© Reuters.  © Reuters.

PARIS (Reuters) - Le groupe pharmaceutique britannique Astrazeneca (NYSE:) a annoncé vendredi le lancement de la phase I/II de son essai clinique au Japon de son candidat-vaccin contre le COVID-19.

Les essais de ce vaccin, baptisé AZD1222, seront menés dans plusieurs installations au Japon et concerneront 250 sujets, a déclaré la société dans un communiqué.

Astrazeneca travaille avec Daiichi Sankyo, JCR Pharma et d'autres partenaires au Japon pour fabriquer et distribuer le vaccin.

(Rocky Swift et Chris Gallagher in Tokyo; Blandine Hénault pour la version française)

Responsabilité: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Let's block ads! (Why?)